Abstract: Disclosed is a method for reducing the appearance of cellulite or improving the texture of skin in a target region of skin that has cellulite or rough skin texture, the method comprising topically applying a composition to the target region that includes an effective amount of a mixture of caffeine, escin, and an aqueous-alcoholic extract from Ascophyllum nodosum, wherein topical application of the composition reduces the appearance of cellulite or improves the texture of the skin.

Abstract: Provided is a tear-free formulation for suppressing or reducing ocular irritancy of a pre-made cosmetic or therapeutic formulation or an ophthalmic formulation suitable for application to an eye of a subject or to a skin region surrounding an eye of a subject.

Abstract: The present invention relates generally to methods and compositions useful for application to skin and hair comprising saccharide isomerate, Alteromonas ferment extract, and a dermatologically acceptable vehicle, wherein the composition is capable of moisturizing and/or improving the appearance and/or condition of skin and/or hair.

Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Abstract: A nutritional supplement that improves energy levels in a human being and a method of administering the same to provide enhanced energy is described. The nutritional supplement comprises fat, caffeine, vitamins and minerals enveloped and surrounded in an edible protective coating. In preferred embodiments, the nutritional supplement is a composition including a fatty matrix supporting caffeine, B vitamins and vitamin D, the fatty matrix is comprised of dark chocolate and the edible protective coating is a sugar shell. The caffeine in the supplement provides for enhanced energy, vitamin D helps to maintain muscle function and strength and supports mental health, and B vitamins facilitate conversion of food or stored energy into active energy. The fatty matrix and edible protective coating cooperate to preserve the nutritional supplement without the need for artificial preservatives.

Abstract: Described herein are compositions, methods, and devices for relief of a cough, cold, sore throat, or allergy, or a related symptom. Also described herein are compositions, methods, and devices for the prevention, treatment and/or amelioration of a digestive illness or digestive discomfort, or a related symptom of either.

Abstract: The invention relates to a medical chewing gum comprising gum base polymers and an active pharmaceutical ingredient, the gum base polymers comprising polyvinyl acetate and vinyl laurate-vinyl acetate copolymer in an amount of more than 90% by weight, wherein the gum base polymers include 20-95% by weight of polyvinyl acetate and -80% by weight of vinyl laurate-vinyl acetate copolymer, and wherein the chewing gum contains no polyterpene resins and no resins based on gum rosin, wood rosin or tall oil resin.

Abstract: The invention relates to respirable dry particles that contain one or more divalent metal cations, such as magnesium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.

Abstract: Single-serve containers for use in brewing a cannabis-based beverage are described, as are methods for preparing a single-serve container configured for receipt in a single-serve brewing machine. The method includes: adding a processed cannabis product to the single-serve container; adding, to the single-serve container, at least one of an extraction or flavoring agent; and sealing the single-serve container.

Abstract: Compositions that can be used to improve human health, and in particular brain health are provided. In some embodiments the composition comprises Inositol, N-Acetyl L-Tyrosine, pyrroloquinoline quinone (PQQ), Choline bitartrate, L-Theanine and Acetyl-L-Carnitine. The compositions may be administered to a subject, for example in the form of a liquid drink, to improve brain health.

Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.

Abstract: The present invention belongs to the fields of pharmacology, medicine and drug delivery. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles comprising microtubule inhibitor such as docetaxel, cabazitaxel and ixabepilone with reduced Ostwald ripening for oral administration.

Abstract: The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.

Abstract: This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.

Abstract: Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition.

Abstract: The present disclosure relates to an oral, extended release, abuse deterrent dosage form containing a controlled release agent, a second agent and/or polyethylene glycol, and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is stable at high temperatures and abuse deterrent to oral and parenteral administration via dose dumping, extraction, and purification. The present disclosure also relates to processes of preparing the dosage form.

Abstract: The present invention relates to a method for preparing polymeric microspheres to improve the drug encapsulating efficiency and, more specifically, to a method for preparing polymeric microspheres, the method comprising the steps of: preparing an internal water phase (w1) and an oil phase (0); mixing the internal water phase and the oil phase to prepare a W1/0 emulsion, followed by cooling; mixing the W1/0 emulsion with an external water phase (W2) to prepare a W1/0/W2 emulsion; and drying the prepared W1/0/W2 emulsion, followed by collection. The method of the present invention can increase the drug encapsulating efficiency and manufacture polymeric microspheres having high drug contents through a procedure of maintaining the step of solidifying the oil phase at a particular temperature for a particular period of time, and thus the method of the present invention is effective in the preparation of sustained release-type drugs.

Abstract: Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.

Abstract: The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site.

Abstract: The present invention concerns use of an agent that increases sphingosine-1-phosphate (S1P) receptor activity, such as S1P, or an S1P receptor agonist, for treatment of alcohol-intoxicated subjects will help stabilize blood pressure and improve resuscitation efforts in alcohol-intoxicated subjects, including alcohol-intoxicated trauma patients. Another aspect concerns a kit for stabilization of alcohol-intoxicated subjects, comprising an agent that increases S1P receptor activity.

Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

Abstract: Methods, compositions of matter, and kits for treatment of breast cancer, and in particular for inflammatory breast cancer, in a patient are disclosed. The methods can include administering a redox modulating agent to the patient. The redox modulating agent can be disulfiram.

Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Abstract: A feed supplement for ruminants to increase milk production, comprised of a carrier and the reaction product of a water soluble polycarboxylic acid, a metal salt, and a C3 to C10 fatty acid, the water soluble carboxylic acid having a pendant carboxylic acid group and being linked to the metal of the metal salt, which is in turn linked to the C3 to C10 fatty acid.

Abstract: A feed supplement energy source for ruminants, swine and poultry comprised of a carrier and the reaction product of a water soluble polycarboxylic acid, a metal salt, and a C3 to C10 fatty acid, the water soluble carboxylic acid having a pendant carboxylic acid group and being linked to the metal of the metal salt, which is in turn linked to the C3 to C10 fatty acid.

Abstract: This invention relates to a naproxen formulation suitable for encapsulation into a soft gel dosage unit by increasing the stability, concentration, and bioavailability of naproxen. Fill formulations of the invention may include other active pharmaceutical ingredients and combinations of two or more active pharmaceutical ingredients. This invention also provides for adjusting pH values of fill formulations without additional process steps. A process for increasing the achievable concentration of an active NSAID pharmaceutical ingredient, such as naproxen, relative to fill composition for dosage units is also provided. The highly concentrated formulation of this invention permits a reduction in the fill volume or dosage unit size, or an increase in concentration of the active pharmaceutical ingredient per dosage form. The invention also relates to a formulation of optimal stability suitable for supporting a fill composition compatible with the soft gel dosage unit.

Abstract: A method is described for treating and/or preventing acne scars wherein an effective amount of a composition including a fixed combination of adapalene or a salt thereof and benzoyl peroxide is administrated to a patient in need thereof. Also described, is a composition that includes a fixed combination of adapalene or a salt thereof and benzoyl peroxide for treating and/or preventing acne scars.

Abstract: Dietary supplements for reducing damage to brain cells characterized by loss of brain cells or loss of brain cell function in patients that have suffered from traumatic brain injury (“TBI”) while participating in sports and/or other athletic events are disclosed herein. The Nutraceutical compositions offer possible ameliorating effects for the secondary phase of TBI. Creatine, vitamin E, zinc, magnesium, DHA, and lipoic acid, taken together, offer a prophylactic measure to ameliorate brain damage that occurs during the secondary phase of SRTBI.

Abstract: Disclosed are methods for treating one or more mammalian cancers, and in particular, methods for treating human breast cancer employing one or more iNOS pathway-inhibitory compounds, either alone, or in combination with one or more selected antihypertensive agents, including calcium channel antagonists, either alone, and further in combination with one or more conventional chemotherapeutic or anti-cancer regimens. Also disclosed are particular therapeutic formulations including these compositions, and methods for their use in treating refractory, metastatic, and relapsed cancers, and for managing or reversing treatment resistance in human triple-negative breast cancers in particular.

Abstract: The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof.

Abstract: Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.

Abstract: The present invention relates to a family of amidino compounds in combination with a hyperosmotic agent or a purinergic agonist for use in a method of treating respiratory disease. More specifically the invention relates to 6-amidino-2-napthyl 4-guanidinobenzoate in combination with a hyperosmotic agent or a purinergic agonist for use in a method of treating respiratory disease such as cystic fibrosis.

Abstract: The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders

Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.

Abstract: A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

Abstract: The invention relates to 3,5,4?-trihydroxy-6,7,3?-trimethoxyflavone (TIF) and achillolid A in prevention or treatment of Alzheimer's disease as well as other neurodegenerative diseases such as Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), ischemia, immunodeficiency virus-1 (HTV-1)-associated dementia, Lewy body associated dementia, traumatic brain injury (TBI), glioma, epilepsy. Huntington's disease, multiple sclerosis, glaucoma and schizophrenia where neuroinflammation, oxidative stress, glutamate toxicity and amyloid beta toxicity are part of the pathophysiology.

Abstract: The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors.

Abstract: A composition and method for rapidly inducing a state of endogenous ketosis, the composition including: about 26.66-28.57 percent by mass of alpha lipoic acid; about 0.01-0.02 percent by mass of chromium picolinate; about 47.61-49.99 percent by mass of L-arginine; and, about 23.33-23.81 percent by mass of calcium carbonate. The method includes restricting carbohydrate consumption to a maximum dosage of about 20 grams prior to consumption of the composition and wherein consumption of the composition is on an empty stomach. About thirty minutes after consumption of the composition the user performs moderate intensity exercise. About three hours after consuming a first dose the user tests for a presence of ketones in urine utilizing at least one sodium nitroprusside urine ketone reagent strip.

Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.

Abstract: Compositions and methods for preventing and treating infection with multi-drug resistant bacteria with AR-13 alone or in combination with antibiotics are provided.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.

Abstract: This invention relates to extended release injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a pharmaceutically acceptable polymer, and a solvent. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the extended release injectable formulations of the invention to the animal in need thereof.

Abstract: This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.

Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).

Abstract: This invention relates to a solution formulation comprising a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a p MDI comprising a canister containing the formulation.

Abstract: Described are novel salts of the compound (3R,4R,5S)-5-(difluoromethyl) piperidine-3,4-diol, as well as methods of using the same for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease and/or Parkinson's disease.

Abstract: This invention provides modified release solid oral dosage form comprising a therapeutically effective amount of pridopidine base, and at least one pharmaceutically acceptable rate controlling excipient.

Abstract: The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.